Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Vyepti Market Grown from 2024 to 2025?
In recent times, the market size of vyepti has experienced an XX (HCAGR). It is projected to expand from a value of $XX million in 2024 to that of $XX million in 2025, showing a compound annual growth rate (CAGR) of XX%. The growth observed in the past years can be linked to an increase in the management of chronic diseases, higher demands for analgesics, a surge in the incidence of targeted diseases, substantial investments in the biopharmaceutical industry, and the growth of home healthcare services.
What Growth Rate Is Anticipated for the Vyepti Market in the Coming Years?
Predictions suggest a significant upward trend in the vyepti market size, with an expected XX (FCAGR) increase in the coming years. It is projected to escalate to a staggering $XX million by 2029, with an impressive compound annual growth rate (CAGR) of XX%. This growth for the projected period can be mainly attributed to the shift towards personalized medical care, the expansion in telemedicine, a surge in consumer interest towards wellness and self-care, an increased emphasis on preventive health services, and the adoption of biosimilars and generic drugs. The forecast period is also likely to see major trends like innovation in drug delivery technologies, progress in drug formulation, the incorporation of wearable devices in treatment monitoring, the application of AI and machine learning in therapeutic decision making, and tech-based innovations in drug manufacturing.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20434&type=smp
Who Are the Leading Companies in the Vyepti Market?
Major companies operating in the vyepti market are H. Lundbeck A/S.
What Are the Key Drivers of the Vyepti Market?
The escalating incidence of migraines is predicted to boost the expansion of the Vyepti market in the future. Migraines, characterized by intense headaches often coupled with other symptoms such as nausea, light or sound sensitivity, and vomiting, are increasingly prevalent due to a mix of lifestyle factors, environmental conditions, and genetic predispositions. These factors may include stress, hormonal variations, certain food triggers and sleep disorder. Vyepti, or eptinezumab, can relieve migraines by specifically targeting the CGRP protein (calcitonin gene-related peptide) that contributes significantly to the emergence of migraine headaches, subsequently diminishing their frequency and severity. Data from the Association of Migraine Disorders released in October 2023 pointed out that migraines impact nearly 1 in 7 people globally, with a strikingly higher incidence in women at 17-19%, compared to 5-7% in men. In the United States alone, more than 35 million people suffer from migraines, the bulk of which are between 35 and 45 years of age. As such, the rising frequency of migraines is fueling the growth of the Vyepti market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20434&type=smp
What Are the Key Market Segments in the Vyepti Industry?
The vyepti market covered in this report is segmented –
1) By Indication: Chronic Migraine; Episodic Migraine; Other Neurological Indications
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
What Are the Latest Trends in the Vyepti Market?
A major development in the vyepti market is the advent of novel therapies, like intravenous (IV) treatment for migraines which aims at improving effectiveness and patient comfort. IV treatment for migraines denotes the delivery of drugs via a vein, offering swift alleviation from severe migraine symptoms and is usually adopted when oral medicines don’t work. For example, in January 2022, the European Commission approved Vyepti (eptinezumab) for the preventative treatment of migraine in adults, developed by H. Lundbeck A/S, a pharmaceutical firm based in Denmark. Vyepti (eptinezumab) is a humanized monoclonal antibody that targets the calcitonin gene-related peptide (CGRP), which plays a significant role in migraine attacks. It is engineered for IV administration, offering quick and prolonged relief from migraine symptoms.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/vyepti-global-market-report
What Are the Key Regional Markets in the Vyepti Industry?
North America was the largest region in the vyepti market in 2024. The regions covered in the vyepti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20434
This Report Delivers Insight On:
1. How big is the vyepti market, and how is it changing globally?
2. Who are the major companies in the vyepti market, and how are they performing?
3. What are the key opportunities and risks in the vyepti market right now?
4. Which products or customer segments are growing the most in the vyepti market?
5. What factors are helping or slowing down the growth of the vyepti market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model